Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui Pharmaceuticals’ investigational cardiovascular disease (CVD) drug in a ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. News. News. Academy. ... Merck Reaches ...

To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from Chinese biotech Hansoh Pharma.

Merck to buy Acceleron for $11 ... “There’s a lot of advances in cardiovascular disease,” Dean Li, president of Merck Research ... The company has rights to market Bayer PAH drug riociguat ...

Merck & Co. will shell out $350 million to acquire NovaCardia, a privately held firm focused on heart disease drugs. NovaCardia's lead product, KW-3902, is a vasodilator in Phase III trials in ...

Cardiome could make $640 million in milestones. Merck & Co. will pay an initial fee of $60 million to Cardiome Pharma for rights to vernakalant, a drug candidate for atrial fibrillation (AF). […] ...

Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from Merck’s $11.5 billion ...